Mogamulizumab as Bridge to Thiotepa-Based Allogeneic Haematopoietic Stem Cell Transplantation in Sézary Syndrome: A Single-Centre Experience [0.03%]
莫加珠单抗作为桥接药物用于塞扎里综合征患者的泰素派为基础的异基因造血干细胞移植的单中心经验
Simone Maifredi,Raffaella Sala,Chiara Bottelli et al.
Simone Maifredi et al.
Introduction: Sézary syndrome (SS) is an aggressive cutaneous T-cell lymphoma for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only potentially curative treatment. ...
Real-World Diagnostic Workup of Patients Suspected for Light Chain Amyloidosis and Wild-Type Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using US Electronic Health Records [0.03%]
利用美国电子健康记录进行的轻链淀粉样变和野生型转甲状腺素蛋白淀粉样心肌病疑似患者的诊断检查:一项回顾性队列研究
Muhamed Baljevic,Haechung Chung,Jose Alvir et al.
Muhamed Baljevic et al.
Introduction: Light chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR-CM) are the most common types of cardiac amyloidosis. Despite similar manifestations, prognosis and treatments are distinct, emphas...
Real-World Outcomes of Thromboprophylaxis With Apixaban in Patients With Newly Diagnosed Multiple Myeloma, the MyelMeXa Study [0.03%]
阿哌沙班在新诊断的多发性骨髓瘤患者中血栓预防的现实世界结果:MyelMeXa研究
K Alexandra Sanchez,Gabriela Cesarman-Maus,Michelle Flores-Cruz et al.
K Alexandra Sanchez et al.
Background: Multiple myeloma (MM) carries a high venous thromboembolism (VTE) risk; aspirin shows limited efficacy, while factor-Xa inhibitors show promise. ...
Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies [0.03%]
抗微生物肽能诱导对靶向疗法耐药的边缘区淋巴瘤模型细胞凋亡
Filippo Spriano,Alberto J Arribas,Fangwen Zhang et al.
Filippo Spriano et al.
Introduction: Marginal zone lymphoma (MZL) is an indolent yet incurable B-cell malignancy in which targeted agents such as BTK and PI3K inhibitors frequently fail due to resistance or toxicity. Antimicrobial peptides (AMP...
Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study [0.03%]
selinexor单药治疗与临床选择治疗经治真性红细胞增多症患者的疗效对比:XPORT-035 II期研究结果
Sebastian Grosicki,Habte Yimer,Rosa Ayala et al.
Sebastian Grosicki et al.
Background: Janus kinase inhibitors (JAKis), the current standard of care for myelofibrosis (MF), provide clinical benefit, but responses are frequently incomplete, non-durable, and associated with cytopenias, underscorin...
Luspatercept in Transfusion-Dependent Thalassemia With Red Blood Cell Antibodies: A Case Series [0.03%]
补体依赖性输血反应的输血依赖型β-地中海贫血患者使用luspatercept治疗的安全性和有效性:系列病例报告
Nattiya Teawtrakul
Nattiya Teawtrakul
Red blood cell (RBC) antibodies complicate transfusion support in transfusion-dependent thalassemia (TDT), and data on luspatercept in this setting remain limited. We retrospectively reviewed seven adults with TDT and RBC antibodies treated...
T-Cell Acute Lymphoblastic Leukemia in a Young Patient With Andersen-Tawil Syndrome Successfully and Safely Treated With Intensive Chemotherapy Including Potential Precipitating Drugs: A Case Report After 3.5 Years of Follow-up [0.03%]
安德森-塔威尔综合征患者的T细胞急性淋巴细胞白血病成功安全地接受了潜在诱发药物联合强化疗:3.5年随访的个案报道
Ramy Rahmé,Paule Moussounda Bamba,Thi Thuy Duong Do et al.
Ramy Rahmé et al.
Andersen-Tawil syndrome (ATS) is a rare, hereditary channelopathy characterized by periodic paralysis, cardiac arrhythmias, and sometimes developmental anomalies. No association with hematologic malignancies has previously been reported. We...
Weekly Cladribine Followed by Rituximab for the Treatment of Hairy Cell Leukemia [0.03%]
cladribine周疗联合利妥昔单抗治疗毛细胞白血病
Jacqueline A Turner,Jennifer Santos,Vincenzo Pizzuti et al.
Jacqueline A Turner et al.
Introduction: Hairy cell leukemia (HCL) is an uncommon hematopoietic stem cell disease known to have an underlying somatic BRAFV600E driver mutation. Currently, the most accepted treatment is five or seven consecutive day...
Durable MRD-Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [0.03%]
在既往治疗线数较多的复发/难治性费城染色体阳性急性淋巴细胞白血病患者中,Blinatumomab和Venetoclax联合治疗可实现持久的MRD阴性缓解
Mohammad Shahzaib Qadir,Shereen Farooq,Omer Jamy
Mohammad Shahzaib Qadir
Introduction: Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resist...
Where Is the 'Oma' in Multiple Myeloma? Origins and Limitations of some Myeloma-Related Terminology [0.03%]
多重骨髓瘤中的“oma”何来何处去——漫谈某些与多发性骨髓瘤相关的术语的起源和局限性
Jecko Thachil,David P Steensma
Jecko Thachil
Background: Multiple myeloma, often simply called 'myeloma', is a clonal plasma cell malignancy that constitutes about one-tenth of all cancers managed by haematologists. Although the disease was first clearly described i...